Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14779305 | 0.85 | GAA (0.43) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4121027 | 0.84 | GAA (0.42) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL8345094 | 0.83 | GAA (0.45) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL13160700 | 0.81 | GAA (0.43) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7806253 | 0.81 | GAA (0.43) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL9508775 | 0.81 | AGER (0.41) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL890642 | 0.80 | GAA (0.50) | AGERGAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL22805528 | 0.80 | VDR (0.51) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL14572925 | 0.80 | VDR (0.51) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL14780279 | 0.80 | CA12 (0.50) | AGERGAAALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4476204-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | Theras, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-110678467-B | Therapeutic compounds and compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-110267957-B | Quinazoline compounds | 安斯泰来制药株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-20220024945-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-10774082-B2 | Quinazoline compound | ASTELLAS PHARMA INC. (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20200140437-A1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200062779-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-10556906-B2 | Quinazoline compound | ASTELLAS PHARMA INC. (JP) | 2020-02-11 | — | — | US | disclosed |
| CN-110678467-A | Therapeutic compounds and compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20180334465-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-03-12 | — | — | US | disclosed |
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2417122-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117932-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117932-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140437-A1 | QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | AGER 3078/4885GAA 2037/4885ALDH1A1 3284/4885 |
| US-10556906-B2 | Quinazoline compound | KRAS, NRAS, HRAS | AGER 3078/4885GAA 2037/4885ALDH1A1 3284/4885 |
| US-20220024945-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | AGER 4435/4885GAA 714/4885ALDH1A1 2322/4885 |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | AGER 4491/4885GAA 2123/4885ALDH1A1 2672/4885 |
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | GPR55, GPR65, GPR35 | AGER 181/4885GAA 1749/4885ALDH1A1 1032/4885 |
| US-10774082-B2 | Quinazoline compound | KRAS, NRAS, HRAS | AGER 3078/4885GAA 2037/4885ALDH1A1 3284/4885 |
| US-20200062779-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | AGER 4435/4885GAA 714/4885ALDH1A1 2322/4885 |
| US-20180334465-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | AGER 4435/4885GAA 714/4885ALDH1A1 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.